PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rituximab - Refractory vasculitis
PAD Profile : Rituximab - Refractory vasculitis
Keywords :
Vasculitis
Brand Names Include :
MabThera
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
- Immune thrombocytopenia
- Rheumatoid arthritis
- Systemic Lupus Erythematosus
- Sjogren's syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Any paediatric use
- ANCA-positive vasculitis
- Connective tissue disease
- Graft versus Host Disease (GVHD)
- Myositis
- Immunoglobulin G4 related disease
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
02 April 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Commissioned by NHS England. Treatment should be initiated by the specialist and is considered to be a RED drug on the traffic light system. GPs should not be requested to prescribe this treatment
01 April 2013
Not Set
Funded by NHS England from 1st April 2013. Treatment should remain with the specialist (RED) hospital only drug.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs